The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer

Ryan Finnegan(Virginia Commonwealth University), David A. Gewirtz(Virginia Commonwealth University)
Frontiers in Oncology
January 18, 2023
Cited by 23


Related Papers